Our team is leading the way to identify the best drugs to stop the most deadly cells responsible for cancer metastasis, spread and recurrence.
Cindy Clark, JD
Serial entrepreneur with 25+ years life science experience (drugs, devices, diagnostics, health information technology, combination products), 5 successful exits, multiple successful product launches, $170M+ in public and private funding, license & collaborations valued at $350M+, federal/state grant and pharma business development experience
Board of Directors
Charles Goldstein, PhD, MSE
Retired Senior Vice President R&D Becton Dickinson; Board member Hale and Proteona; Advisor, Johns Hopkins University – Whiting School of Engineering
Konstantinos Konstantopoulos, PhD
William H. Schwarz Professor of Chemical and Biomolecular Engineering, Biomedical Engineering and Oncology at Johns Hopkins, Project leader NCI-funded JHU Physical Sciences-Oncology Center, PI of multiple NIH R01 grants, numerous awards, serves on editorial boards of several scientific journals.